Inhibition of osteolytic bone metastasis by unfractionated heparin

Clinical and Experimental Metastasis

Volumn 25, Issue 8, 2008, Pages 903-911

  Yee, Colin K ^a   Butcher, Martin ^a   Zeadin, Melec ^a   Weitz, Jeffrey I ^a   Shaughnessy, Stephen G ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Bone metastasis; Heparin; Melanoma

Indexed keywords

HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE STRENGTH; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; MELANOMA; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOLYSIS;

ANIMALS; ANTICOAGULANTS; BONE AND BONES; BONE DENSITY; BONE NEOPLASMS; FEMALE; FEMUR; GREEN FLUORESCENT PROTEINS; HEPARIN; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OSTEOLYSIS; TUMOR BURDEN;

EID: 57049167583     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-008-9212-0     Document Type: Article

References (47)

1. GR Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 584 593 10.1038/nrc867
2. NJ Carty A Foggitt CR Hamilton 1995 Patterns of clinical metastasis in breast cancer: an analysis of 100 patients Eur J Surg Oncol 21 607 608 10.1016/S0748-7983(95)95176-8
3. B Naume E Borgen G Kvalheim 2001 Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics Clin Cancer Res 7 4122 4129
4. B Taback AE Giuliano NM Hansen 2003 Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients Cancer Res 63 1884 1887
5. AK Kakkar AR Hedges RCN Williamson 1995 Perioperative heparin therapy inhibits late deaths from metastatic cancer Int J Oncol 6 885 888
6. Lebeau B, Chastang C, Brechot JM et al (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74:38-45. doi :10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E
7. P Prandoni AWA Lensing HR Buller 1992 Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis Lancet 339 441 445 10.1016/0140-6736(92)91054-C
8. GF von Tempelhoff J Harenberg F Niemann 2000 Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial Int J Oncol 16 815 824
9. M Altinbas HS Coskun O Er 2004 A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 1266 1271 10.1111/j.1538-7836.2004.00871.x
10. AK Kakkar MN Levine Z Kadziola 2004 Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 1944 1948 10.1200/JCO.2004.10. 002
11. SM Smorenburg R Vink HM Otten 2001 The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis Thromb Haemost 86 1586 1587
12. J Hirsh TE Warkentin SG Shaughnessy 2001 Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety Chest 119 64S 94S 10.1378/chest.119.1_suppl.64S
13. DL Rabenstein 2002 Heparin and heparan sulfate: structure and function Nat Prod Rep 19 312 331 10.1039/b100916h
14. HA Harrop CC Rider 1998 Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4 Glycobiology 8 131 137 10.1093/glycob/8.2.131
15. AL Howell TH Taylor JD Miller 1996 Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS Int J Clin Lab Res 26 124 10.1007/BF02592355
16. RM Nelson O Cecconi WG Roberts 1993 Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation Blood 82 3253 3258
17. DJ Tyrrell AP Horne KR Holme 1999 Heparin in inflammation: potential therapeutic applications beyond anticoagulation Adv Pharmacol 46 151 208 10.1016/S1054-3589(08)60471-8
18. JM Muir M Andrew J Hirsh 1996 Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo Blood 88 1314 1320
19. JM Muir J Hirsh JI Weitz 1997 A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats Blood 89 3236 3242
20. TA Einhorn 1992 Bone strength: the bottom line Calcif Tissue 51 333 339 10.1007/BF00316875
21. Rubin CT, Rubin J (1999) Biomechanics of bone. In: Favus M (ed) Primer on the metabolic bone diseases and disorders of mineral. Lippincott, Williams and Wilkins, Philadelphia, pp 39-42
22. RJ Ludwig S Alban R Bistrian 2006 The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo Thromb Haemost 95 535 540
23. B Bereczky R Gilly E Raso 2005 Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest Clin Exp Metastasis 22 69 76 10.1007/s10585-005-3859-6
24. SA Mousa R Lindhardt JL Francis 2006 Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin Thromb Haemost 96 816 821
25. RJ Ludwig B Boehme M Podda 2004 Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis Cancer Res 64 2743 2750 10.1158/0008-5472.CAN-03-1054
26. JR Canon M Roudier R Bryant 2008 Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis Clin Exp Metastasis 25 119 129 10.1007/s10585-007-9127-1
27. S Morony C Capparelli I Sarosi 2001 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis Cancer Res 61 4432 4436
28. J Zhang J Dai Y Qi 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone J Clin Invest 107 1235 1244 10.1172/JCI11685
29. Yoneda T, Michigami T, Yi B et al (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979-2988. doi :10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U
30. SH Tannehill-Gregg AL Levine MVP Nadella 2006 The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice Clin Exp Metastasis 23 19 31 10.1007/s10585-006-9008-z
31. SG Shaughnessy E Young P Deschamps 1995 The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria Blood 86 1368 1373
32. C Shigemori H Wada K Matsumoto 1998 Tissue factor expression and metastatic potential of colorectal cancer Thromb Haemost 80 894 898
33. V Kaushal P Mukunyadzi ER Siegel 2008 Expression of tissue factor in prostate cancer correlates with malignant phenotype Appl Immunohistochem Mol Morphol 16 1 6
34. T Ueno M Toi M Koike 2000 Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration Br J Cancer 83 164 170 10.1054/bjoc.2000.1272
35. BM Mueller RA Reisfeld TS Edgington 1992 Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis Proc Natl Acad Sci USA 89 11832 11836 10.1073/pnas.89.24.11832
36. E Camerer AA Qazi DN Duong 2005 Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis Blood 104 397 401 10.1182/blood-2004- 02-0434
37. S Karpatikin E Pearlstein C Ambrogio 1988 Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo J Clin Invest 81 1012 1019 10.1172/JCI113411
38. SA Cohen M Trikha MA Mascelli 2000 Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular oncological indications Pathol Oncol Res 6 163 174
39. A Amirkhosravi SA Mousa M Amaya 2004 Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GPIIb/IIIa antagonist XV454 Thromb Haemost 90 549 554
40. JL Stevenson SH Choi A Varki 2005 Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity Clin Cancer Res 11 7003 7011 10.1158/1078-0432.CCR-05- 1131
41. L Borsig 2004 Selectins facilitate carcinoma metastasis and heparin can prevent them News Physiol Sci 19 16 21 10.1152/nips.01450.2003
42. R Kannagi 1997 Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer Glycoconj J 14 577 584 10.1023/A:1018532409041
43. L Borsig R Wong J Feramisco 2001 Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins and tumor metastasis Proc Natl Acad Sci USA 98 3352 3357 10.1073/pnas.061615598
44. M Takita M Inada T Maruyama 2007 Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells FEBS Lett 581 565 571 10.1016/j.febslet.2007.01.005
45. 3 integrins are critical for bone metastasis Proc Natl Acad Sci USA 100 14205 14210 10.1073/pnas.2234372100
46. M Monreal E Lafoz A Olive L del Rio C Vedia 1994 Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to Coumarin Thromb Haemost 71 7 11
47. V Pettila P Leinonen A Markkola V Hiilesmaa R Kaaja 2002 Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin Thromb Haemost 87 182 196